Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 12/20 | 0.77 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.66 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.65 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.65 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3902547 | 1.00 | SLC29A1 (0.77) | SLC29A1ADORA3DNMT1DNMT3BDOT1L | |
| Hydrochloric Acid SCHEMBL8577234 | 0.99 | SLC29A1 (0.75) | SLC29A1ADORA3DNMT1DNMT3BDOT1L | |
| SCHEMBL8572281 | 0.93 | SLC29A1 (0.80) | SLC29A1ADORA3DNMT1DNMT3BDOT1L | |
| SCHEMBL8572278 | 0.93 | SLC29A1 (0.80) | SLC29A1ADORA3DNMT1DNMT3BDOT1L | |
| SCHEMBL638749 | 0.87 | SLC29A1 (1.00) | SLC29A1ADORA3 | |
| SCHEMBL20626431 | 0.87 | SLC29A1 (1.00) | SLC29A1ADORA3 | |
| SCHEMBL3895881 | 0.87 | SLC29A1 (1.00) | SLC29A1ADORA3 | |
| SCHEMBL638750 | 0.87 | SLC29A1 (1.00) | SLC29A1ADORA3 | |
| SCHEMBL14713263 | 0.87 | SLC29A1 (1.00) | SLC29A1ADORA3 | |
| SCHEMBL14688879 | 0.82 | DNPH1 (0.79) | SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | DRUG INNOVATION & DESIGN, INC. | 2003-07-24 | — | — | US | disclosed |
| EP-1255567-A1 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | Drug Innovation & Design, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001036003-A2 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | DRUG INNOVATION & DESIGN, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
| US-RE35904-E | COMPOUND CAPABLE OF BINDING TO ES NUCLEOSIDE TRANSPORTER OF ANIMAL CELLS | GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 1998-09-22 | — | — | US | disclosed |
| US-5236902-A | Method and probes for detecting nucleoside transporter and method for producing the probes | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 1993-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | PAICS, ABCB1, ABCG2 | SLC29A1 55/4885ADORA3 943/4885DNMT1 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.